Breast Cancer

FDA Clearance Received To Market Advancement in Cancer Monitoring

Published in Cancer Weekly, June 30th, 1997

Centocor, Inc., Malvern, Pennsylvania, announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its CA 15-3 serum tumor marker radioimmunoassay (RIA), an important advancement in disease monitoring for patients with breast cancer.

The CA 15-3 RIA, when used in conjunction with other clinical and diagnostic methods, is a valuable adjunct in the overall management of breast cancer patients.

Developed and brought to market in other countries by Centocor since 1985, the CA 15-3 RIA is now available for use in the U.S. Through a distribution agreement with Fisher Scientific, of Houston, Texas, the CA 15-3 RIA is...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-06-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry